---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-051028"
form_type: "8-K"
ticker: "ADVB"
cik: "0001941029"
company_name: "Advanced Biomed Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:23:10.146600+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Advanced Biomed completes AI pivot with acquisition of Acellent Technologies

## Summary
- Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.
- Strategic pivot from life sciences to AI development; CEO Yi Lu mutually separated, receives 39,999 shares as severance.
- Xiaomin Chen appointed CEO, director, and chairman effective April 28; he has 20+ years AI experience including Google.
- Chen's base salary set at $12,000/month; eligible for bonuses and equity incentives.
- Chen is the sole shareholder of the acquired entity, creating a direct material interest in the transaction.

## SEC filing metadata
- accession: 0001213900-26-051028
- form_type: 8-K
- ticker: ADVB
- cik: 0001941029
- company_name: Advanced Biomed Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/ea0288766-8k_advanced.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-051028
- JSON: https://secwatch.observer/filing/0001213900-26-051028.json
- Plain text: https://secwatch.observer/filing/0001213900-26-051028.txt

## Key facts
- Equity Issuances
  Advanced Biomed Inc. issued 270,000 shares of common stock to Mr. Xiaomin Chen for $1,080,000.
  - Security: common stock
  - Shares: 270,000 shares
  - Purchaser: Mr. Xiaomin Chen
  - Consideration: $1,080,000
  source text: n aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026. Item 3.02 Unregistered Sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm
- Executive change
  Xiaomin Chen was appointed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..
  - Action: appointed
  - Role: Chief Executive Officer, director and Chairman of the Board
  source text: the Board of Directors appointed Mr. Xiaomin Chen as Chief Executive Officer, director and Chairman of the Board of the Company, effective as of April 28, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm
- Executive change
  Yi Lu departed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..
  - Action: mutually agreed to separate
  - Role: Chief Executive Officer, director and Chairman of the Board
  source text: The Company and Mr. Yi Lu, the Company’s Chief Executive Officer, director and Chairman of the Board, have mutually agreed that a leadership transition is necessary and in the best interests of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm
- M&A Transactions
  Advanced Biomed Inc. completed an acquisition involving Acellent Technologies (Hong Kong) Co. Limited for $1,080,000 (closed 2026-04-30).
  - Action: acquisition
  - Counterparty: Acellent Technologies (Hong Kong) Co. Limited
  - Consideration: $1,080,000
  - Closing: 2026-04-30
  source text: Pursuant to the Share Purchase Agreement, the Company agreed to acquire 100% of the equity interest in the Target in exchange for the issuance of 270,000 shares of the Company’s common stock, par value $0.001 per share, valued at $4.00 per share, for an aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.